Brokerages Set Nektar Therapeutics (NASDAQ:NKTR) Price Target at $1.50

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has earned a consensus recommendation of “Hold” from the five brokerages that are presently covering the company, Marketbeat reports. One analyst h… [+3481 chars]

Ads Links by Easy Branches
Play online games for free at games.easybranches.com

Guest Post Services www.easybranches.com/contribute
Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Prediction of antimicrobial resistance of Klebsiella pneumoniae from genomic data through machine learning
Howard W. Robin Sells 14,881 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock